{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:26:31Z","timestamp":1784193991358,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jim.2021.113164","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T03:12:08Z","timestamp":1633489928000},"page":"113164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Application of a caprylate\/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma"],"prefix":"10.1016","volume":"499","author":[{"given":"Michelle","family":"Woznichak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Vandeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Talton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vik","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Keither","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2021.113164_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1006\/biol.1999.0234","article-title":"Viral inactivation of intramuscular immune serum globulins","volume":"28","author":"Alonso","year":"2000","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2021.113164_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biologicals.2020.01.004","article-title":"Immune globulin subcutaneous, human 20% solution (Xembify(R)), a new high concentration immunoglobulin product for subcutaneous administration","volume":"64","author":"Alonso","year":"2020","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2021.113164_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.biologicals.2012.04.003","article-title":"Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process","volume":"40","author":"Barnette","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2021.113164_bb0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/21645515.2015.1085142","article-title":"Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies","volume":"12","author":"Bharti","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jim.2021.113164_bb0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/21645515.2016.1255834","article-title":"Injecting rabies immunoglobulin (RIG) into wounds only: a significant saving of lives and costly RIG","volume":"13","author":"Bharti","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jim.2021.113164_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jim.2021.113164_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/jcm.3.2.96-101.1976","article-title":"Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine","volume":"3","author":"Cox","year":"1976","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jim.2021.113164_bb0040","series-title":"Privigen\u00ae[immune Globulin Intravenous (Human) 10% Liquid] \u2013 Package Insert","author":"CSL Behring AG","year":"2019"},{"key":"10.1016\/j.jim.2021.113164_bb0045","series-title":"Hizentra\u00ae [Immune Globulin Subcutaneous (Human) 20% Liquid] \u2013 Package Insert","author":"CSL Behring AG","year":"2021"},{"key":"10.1016\/j.jim.2021.113164_bb0050","series-title":"Activated Coagulation Factors. Monograph 2.6.22","author":"European Pharmacopeia","year":"2010"},{"key":"10.1016\/j.jim.2021.113164_bb0055","series-title":"HyperHEP B\u00ae [Hepatitis B Immune Globulin (Human)] \u2013 Package Insert","author":"Grifols Therapeutics, LLC","year":"2020"},{"key":"10.1016\/j.jim.2021.113164_bb0060","series-title":"HyperTET\u00ae [Tetanus Immune Globulin (Human)] \u2013 Package Insert","author":"Grifols Therapeutics, LLC","year":"2020"},{"key":"10.1016\/j.jim.2021.113164_bb0065","series-title":"HyperRAB\u00ae [Rabies Immune Globulin (Human)] Solution for Infiltration and Intramuscular Injection - Package Insert","author":"Grifols Therapeutics, LLC","year":"2021"},{"key":"10.1016\/j.jim.2021.113164_bb0070","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jim.2021.113164_bb0075","first-page":"79","article-title":"Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate\/chromatography purified","volume":"10","author":"Hanna","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.jim.2021.113164_bb0080","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(00)04852-2","article-title":"Human rabies and bat bites","volume":"357","author":"Jackson","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jim.2021.113164_bb0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1128\/AAC.18.6.962","article-title":"Interaction of polyunsaturated fatty acids with animal cells and enveloped viruses","volume":"18","author":"Kohn","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jim.2021.113164_bb0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","article-title":"Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates","volume":"30","author":"Korneyeva","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2021.113164_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography","volume":"84","author":"Lebing","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.jim.2021.113164_bb0100","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2460\/javma.253.12.1555","article-title":"Rabies surveillance in the United States during 2017","volume":"253","author":"Ma","year":"2018","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.jim.2021.113164_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2460\/javma.256.2.195","article-title":"Public veterinary medicine: public health: rabies surveillance in the United States during 2018","volume":"256","author":"Ma","year":"2020","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.jim.2021.113164_bb0110","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.jim.2021.113164_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12665\/J161.Nims","article-title":"Identification of worst-case model viruses for low and high pH inactivation","volume":"16","author":"Nims","year":"2017","journal-title":"Bioprocess. J."},{"key":"10.1016\/j.jim.2021.113164_bb0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jim.2021.113164_bb0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5731\/pdajpst.2016.007393","article-title":"Development of a premium quality plasma-derived IVIg (IQYMUNE\u00ae) utilizing the principles of quality by design \u2013 a worked-through case study","volume":"72","author":"Paolantonacci","year":"2018","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jim.2021.113164_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.15585\/mmwr.mm6823e1","article-title":"Vital signs: trends in human rabies deaths and exposures \u2013 United States 1938-2018","volume":"68","author":"Pieracci","year":"2019","journal-title":"Morb. Mortal. Week. Rep."},{"key":"10.1016\/j.jim.2021.113164_bb0135","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1373\/clinchem.2003.022350","article-title":"IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents","volume":"49","author":"Schauer","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jim.2021.113164_bb0140","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/trf.12280","article-title":"Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography","volume":"54","author":"Seifner","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jim.2021.113164_bb0145","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jim.2021.113164_bb1000","doi-asserted-by":"crossref","unstructured":"Vandeberg, Peter, Maria Cruz, Jos\u00e9 Mar\u00eda Diez, W. Keither Merritt, Benjamin Santos, Susan Trukawinski, Andrea Wellhouse, Marta Jos\u00e9, and Todd Willis. \"Brief report: Production of anti\u2010SARS\u2010CoV\u20102 hyperimmune globulin from convalescent plasma.\" Transfusion (2021).","DOI":"10.1101\/2020.11.18.388991"},{"key":"10.1016\/j.jim.2021.113164_bb0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijpharm.2015.05.069","article-title":"Tolerability of hypertonic injectables","volume":"490","author":"Wang","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jim.2021.113164_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/clinids\/22.2.228","article-title":"Failure of postexposure treatment of rabies in children","volume":"22","author":"Wilde","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jim.2021.113164_bb0160","doi-asserted-by":"crossref","first-page":"AB10","DOI":"10.1016\/j.jaci.2012.12.712","article-title":"Removal of coagulation factors by the Gamunex\u00ae-C purification process","volume":"131","author":"Williams","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jim.2021.113164_bb0165","first-page":"1","article-title":"WHO expert consultation on rabies. Third report","author":"World Health Organization","year":"2018","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.jim.2021.113164_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-3083.2011.02537.x","article-title":"Monomeric and dimeric IgG fractions show differential reactivity against pathogen-derived antigens","volume":"74","author":"Wymann","year":"2011","journal-title":"Scand. J. Immunol."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217592100209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217592100209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:38:58Z","timestamp":1758299938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002217592100209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"alternative-id":["S002217592100209X"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2021.113164","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of a caprylate\/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2021.113164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113164"}}